Bill Proposes 10 Additional Years for COVID-19 Inventions

MoFo Life Sciences
Contact

MoFo Life Sciences

A proposed bill offers a potential boon to patent owners. If passed, the “Facilitating Innovation to Fight Coronavirus Act” will add ten years to the patent term of eligible inventions. However, the bill will temporarily curtail patent owner enforcement rights. Passage is not certain, with a number of critical issues for Congress to iron out.

Eligibility requires the patented invention to be useful for combatting COVID-19. Specifically, eligible patents must be “used or intended for use in the treatment of the Coronavirus Disease 2019 (COVID-19).” The proposed bill does not explain what inventions are “used or intended for use in the treatment of” COVID-19 and so the scope of eligibility needs clarification.

The bonus decade will not be free. In exchange for the term extension, patentees must set aside their right to exclude until the executive revokes the national state of emergency. Until that revocation, an eligible invention is available for public use. Upon return of rights to the patent owner, patent term will extend “10 years longer than it otherwise would” under Title 35.

The proposed bill leaves many important questions unanswered. For example, how will the public return IP rights to the patentee? Can a patentee elect to opt out and instead enforce a patent during the national state of emergency? Are the ten years added after other patent term adjustments? Does the bill apply to patents that were in force before the effective date of the Act or just to patents that issue after that date? Further, the bill, if passed, will create precedent for temporary override of patent rights, which faces strong headwinds from patent owner lobbyists. Given that critical questions remain unanswered and the likely resistance, the bill will need significant changes before (and if) it passes.

We will continue to monitor the trajectory of the Act and update this post as necessary.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© MoFo Life Sciences | Attorney Advertising

Written by:

MoFo Life Sciences
Contact
more
less

MoFo Life Sciences on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.